Merck and Eisai's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA's Third Breakthrough Therapy Designation as 1L Therapy for Hepatocellular Carcinoma
Shots:
- The third BT designation is based on P-Ib KEYNOTE-524 study assessing Keytruda (200mg- IV- q3w) + Lenvima (12/8 mg/day) in patients with unresectable HCC not amenable to locoregional treatment
- The dual regimen has received its first two BT designation for advanced and metastatic renal carcinoma and non-microsatellite instability-high/proficient mismatch repair endometrial carcinoma in Jan’18 and Jul’18- respectively
- Keytruda is an anti-PD-1 therapy blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activate T lymphocytes affecting both tumor & healthy cells. Eisai’s Lenvima is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR 1- 2 & 3
Click here to read full press release/ article
Ref: Merck | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com